IDT Biologika GmbH
Dessau-Roßlau, Germany
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (4)
○ EMA GMP
○ MHRA GMP
Quick Facts: IDT Biologika GmbH
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- Dessau-Roßlau, Germany
- Modalities
- Viral Vaccines (live, inactivated, BSL-2), AAV, Adenoviral Vectors, Lentiviral Vectors, Gene & Immune Therapeutics, Oncolytic Viruses, Monoclonal Antibodies, Recombinant Proteins / Biosimilars, Sterile Fill-Finish (liquid, lyophilized, vials, pre-filled syringes)
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About IDT Biologika GmbH
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesViral Vaccines (live, inactivated, BSL-2), AAV, Adenoviral Vectors, Lentiviral Vectors, Gene & Immune Therapeutics, Oncolytic Viruses, Monoclonal Antibodies, Recombinant Proteins / Biosimilars, Sterile Fill-Finish (liquid, lyophilized, vials, pre-filled syringes)
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (9 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press4 articles
Broad modality coverage (9 modalities)
Recent News 4 articles
IDT Biologika Accelerates Global CDMO Expansion Manufacturing capabilities highlighted through consecutive participation in WVC, CPHI and BIO-Europe 2025 - PR Newswire
Takeda taps Biological E to ramp up Qdenga manufacturing capacity on quest to make 100M doses a year - Fierce Pharma
From the experts: How to successfully implement Annex 1 regulations - Pharmaceutical Technology
SK Bioscience begins 'globalization' push, paying $244M for majority stake in contract manufacturer IDT Biologika - Fierce Pharma
Frequently Asked Questions About IDT Biologika GmbH
What is IDT Biologika GmbH's CDMO Signal Score?
IDT Biologika GmbH has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating IDT Biologika GmbH for a manufacturing program?
Use the free AI matchmaker to compare IDT Biologika GmbH against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 91.7
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
ReciBioPharm
Keele, UK · Sodertalje, SE
Signal Score: 88.0
AAV, Lentiviral, Plasmid, mRNA
Pharmaron Biologics
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
Signal Score: 86.9
AAV, Lentiviral, Plasmid, mAb, Antibody, Recombinant Protein, Biosimilars
Ajinomoto Bio-Pharma Services
San Diego, CA · Osaka, JP
Signal Score: 85.6
Oligonucleotide, Biologics, AAV
Lotte Biologics
Incheon, KR · Syracuse, NY
Signal Score: 83.7
Biologics, AAV